GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
Business Wire•19/10/2026•16:05 ET
0
Key Highlights
- ➤27 abstracts presented at ASHG 2026 span rare disease, autism, newborn screening and genomic medicine
- ➤More than 100,000 autism cases studied to assess molecular diagnostic yield from exome sequencing
- ➤GUARDIAN findings cover positive rates and variants in more than 19,000 newborns
- ➤Nine abstracts use GeneDx Infinity, GeneMatcher and collaborations to identify novel disease genes
- ➤Three presentations, three rapid-fire talks and one Reviewer’s Choice poster included
Expert Statements
Linda Genen, Chief Medical Officer at GeneDx
“Advancing genomic medicine means turning scientific discovery into meaningful answers for patients”
Linda Genen, Chief Medical Officer at GeneDx
“Through our clinical data, technology and research collaborations, we’re building the evidence to make exome and genome sequencing a more accessible and actionable part of care across specialties and throughout life.”
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
Research strengthens the evidence for exome and genome sequencing as standard of care across rare disease, autism, newborn screening and beyond
Get started
Create a free account to read the full story.